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C ancer is initiated when healthy cells, in a stepwise fashion, accumulate DNA mutations in 
oncogenes and tumor-suppressor genes. 
Due to these mutations, cells acquire the 
capacity to escape cellular mechanisms 
that prevent unscheduled cell growth, 
causing rapid and uncontrolled cell 
division.(1) When cancer cells are not 
eradicated timely, some tumors can 
eventually grow out and acquire the 
ability to metastasize throughout the 
body. If  no successful therapeutic 
intervention is provided, the disease will 
ultimately result in organ failure and 
death. Indeed, cancer is the responsible 
cause of  death for approximately 8,7 
million people worldwide in 2015 alone.
(2)
If  cancer remains locally confined, 
surgical removal is possible and can 
lead to curation, but for treatment of  
metastasized disease, chemotherapy 
and/or radiotherapy might be required. 
However, both these treatment options 
are harmful for normal cells. Damage 
to healthy tissues strongly limits the 
chemo and radiotherapy dose that can be 
tolerated, and thereby limits the cancer 
killing efficacy of  cancer treatments.
(3) Furthermore, while patients often 
show remission following chemo and 
radiotherapy many tumors are not 
completely eradicated, resulting in 
patient relapse.
To resolve these issues, a more selective 
or ‘targeted’ approach is required, 
which seizes upon processes essential 
for cancer cell survival, but dispensable 
for non-transformed ‘healthy’ cells. An 
important example hereof  is ‘oncogene 
addiction’, in which oncogenic growth 
is reliant on signal transduction 
arising from genetic oncogenic 
events. Specifically, cancer cells can 
get ‘addicted’ to signaling induced by 
activating mutations or overexpression 
of  EGFR family members, and BCR-
ABL translocations.(4,5) Because tumor 
cells are ‘addicted’ to such oncogene 
signaling and healthy cells are not, this 
provides a therapeutic opportunity to 
kill tumor through targeting inhibition 
of  the hyperactivated oncogene. 
Conversely, some tumors become reliant 
on pathways that are not oncogenic, a 
process called ‘non-oncogene addiction’.
(6) For instance, tumor cells may be 
increasingly dependent on DNA repair 
or certain metabolic pathways, whereas 
these pathways are not oncogenic 
themselves, and therefore again provide 
a therapeutic window.
 Another form of  targeted 
therapy is based on the concept of  
synthetic lethality. In this concept, a 
mutation in a specific gene is lethal 
only when present in combination 
with another specific mutation. Such 
a combination of  gene mutations is 
called synthetic lethal. This concept 
is highly relevant for cancer cells, in 
which a specific gene mutation makes 
these cells completely reliant for their 
survival on the function of  another 
gene. This latter gene could thus serve 
as a therapeutic target.(7) A well-known 
application of  synthetic lethality is the 
use of  PARP inhibitors in tumors with 
a defect in homologous-recombination 
(HR) DNA repair. Two important genes 
involved in HR are BRCA1 or BRCA2, 
mutations in which cause hereditary 
breast and ovarian cancer. Indeed, cells 
lacking functional BRCA1 or BRCA2 
were shown to be extremely sensitive 
to inhibitors of  the PARP enzyme.
(8,9) Conversely, healthy cells that 
possess functional BRCA genes are not 
sensitive to PARP inhibition, allowing 
for tumor clearance without excessive 
side-effects. Unfortunately, however, 
tumors often develop resistance to 
PARP inhibitor therapy.(10) Therefore, 
a better understanding of  how PARP 




improve their efficacy by developing 
combination strategies. Additionally, 
only a relatively small subset of  cancers 
has dysfunctional BRCA genes. The 
identification of  other gene mutations 
that also cause a HR-defect could 
broaden the group of  eligible patients 
for PARP inhibitor treatment. Yet, in 
spite of  the clinical successes of  PARP 
inhibitors, resistance mechanisms have 
been reported and, since only certain 
subgroups are eligible, additional 
mechanisms are required to selectively 
target all tumors 
Additionally, owing to their frequent 
oncogene activation and consequent 
uncontrolled division, cancer cells 
regularly suffer from slowed or even 
stalled replication, a process called 
replication stress. Indeed, replication 
defects are thought to be an important 
underlying cause in the acquisition of  
mutations and genomic rearrangements 
that entail genomic instability. Notably, 
induction of  replication stress or 
genomic instability in non-cancerous 
cells was shown to be lethal.(11) 
Apparently, cancer cells have evolved 
mechanisms to cope with high levels 
of  replication stress and genomic 
instability. Therefore, targeting of  these 
pathways could also be an interesting 
strategy to selectively kill cancer cells.
(12,13)
The aim of  this thesis is therefore to: 
1. Uncover the synthetically lethal 
mechanisms underlying PARP inhibitor-
induced cell death in HR-deficient 
cancer cells, and to use these insights to 
develop new combination strategies. 
2. Target replication stress to selectively 
kill cancer cells.
 
OUTLINE OF THIS THESIS
In chapter 2 of  this thesis, we discuss 
cancer-relevant factors that challenge 
the replication machinery and, how 
these factors induce replication 
stress. Furthermore, we explain how 
replication stress drives genomic 
instability in promoting cancer 
development. Lastly, we describe the 
mechanisms employed by cells to deal 
with replication stress, and how these 
mechanisms may provide therapeutic 
targets to kill cancers harboring 
replication stress. Special emphasis is 
placed on recent findings that show that, 
in conditions of  replication stress, DNA 
replication can persist in mitosis, where 
it leads to the formation of  chromatin 
bridges in anaphase, which can cause 
multinucleation and cell death when left 
unresolved. 
Mutations in essential HR genes, 
including BRCA1 and BRCA2, cause 
susceptibility to cancer development. 
Yet, BRCA1/2-mutant cancer cells 
have an elevated sensitivity towards 
PARP inhibition treatment. While 
PARP inhibitors show great promise 
as a treatment strategy, not all 
tumors respond to PARP inhibition. 
Additionally, some tumors develop 
resistance, which causes tumor relapse. 
More insight into the mechanisms-of-
action of  PARP inhibitors is therefore 
required to improve therapy outcome. 
Specifically, it is still unclear how exactly 
PARP inhibitors kill HR-deficient cells. 
To address this question, in chapter 3 
we study the underlying mechanisms 
of  PARP inhibitor cytotoxicity. To 
this end, we use multiple HR-deficient 
cancer models both in vitro and in vivo 
and follow the induction of  PARP-
inhibitor-induced replication stress 
throughout the cell cycle using both 
immuno-fluorescence microscopy and 
live-cell imaging. Lastly, we assess 




was essential for PARP inhibitor-
induced toxicity. To this end, EMI1 
depletion was used to bypass mitosis, 
while leaving the ability of  cells to 
perform DNA replication intact. 
In chapter 4, we further explore the 
mechanism underlying PARP inhibitor-
induced cytotoxicity as discovered 
in chapter 3. Specifically, a possible 
combination strategy is tested, involving 
combined inhibition of  PARP and ATR, 
a central orchestrator in the replication 
stress response. We determine the 
timing of  mitotic entry by flow 
cytometric analysis of  synchronized 
cell populations, in the presence of  
ATR/PARP inhibitors. Furthermore, 
we assess possible mitotic aberrancies 
and genomic instability using immuno-
fluorescence and single cell sequencing.
The overexpression of  certain 
oncogenes is a well-described cause of  
replication stress, which possibly fuels 
genetic instability and cancer. However, 
the resulting replication stress can 
also prove to be a therapeutically 
exploitable weakness in cancers. To 
test this hypothesis in chapter 5, we 
set out to develop inducible oncogene 
overexpression models in non-
transformed RPE-1 cells. Subsequently, 
we investigated if  overexpression of  
these oncogenes resulted in replication 
stress and whether the DNA lesions 
caused by replication stress were 
transferred into mitosis. Additionally, 
we attempted to target cells with 
oncogene-induced replication stress 
by inhibition of  the ATR and WEE1 
checkpoint kinases. Lastly, the effects on 
mitotic aberrancies were studied in real-
time using live-cell microscopy.
To allow for proper sister chromatid 
disjunction during anaphase, cells are 
equipped with topoisomerase II, Plk1-
interacting checkpoint helicase (PICH) 
and Bloom’s helicase (BLM). This 
machinery resolves DNA catenanes, 
which are visible as ultrafine DNA 
bridges (UFBs) in anaphase. Since 
failure to resolve UFBs can impair 
genomic integrity, identifying novel 
players involved in this process is of  
great interest. In chapter 6, we studied 
the function of  Rif1 in mitosis. Using 
immune-fluorescence and live-cell 
imaging, we determine whether Rif1 
was involved in a mitotic DNA damage 
response. Furthermore, the localization 
of  Rif1 and its role in maintaining 
genome integrity will be assessed. 
Lastly, in chapter 7 the results and 
conclusions of  all chapters will be 
summarized and discussed. We revisit 
the aims established in the introduction, 
and discuss implications and future 
directions.
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